40 ERIE STREET, CAMBRIDGE, MA
Announces First Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics Enters Underwriting Agreement for Public Offering
Reg. FD, Other Events
Amendments to By-laws Adopted by Intellia Therapeutics Board
Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
Investor Presentation
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Confidential Treatment Order
Correspondence
Submission Upload